Trending in 'Health'

HEALTH & WELLBEING | INVESTIGATIVE REPORT

Why Your GP Never Told You About the 1957 Discovery That 'Switches Off' Nerve Pain

While the NHS prescribed Pregabalin and Gabapentin, this natural molecule sat in university archives for 67 years. Now British researchers reveal how ultra-micronised PEA targets the 'glial cell fires' causing your agony—without the fog, without the risk.

By Dr. Eleanor Hartley, Medical Correspondent

3,791 Ratings | January, London 2026

Phil Kay, 61, used to walk six kilometres every morning through the parks of Bristol.

 

A retired electrician with steady hands and a steadier routine, he prided himself on never missing a day.

 

Then, one October morning two years ago, his left foot began to burn.

 

"It felt like someone had poured hot coals into my boot," he recalls. "But when I looked, there was nothing. No wound. No rash. Just this... fire."

 

Within weeks, the burning had spread to both feet, then his calves. Sleep became impossible...

 

His GP prescribed paracetamol—useless. Then ibuprofen—equally pointless...

 

Finally, after a four-month wait for a specialist referral that never materialised, Phil was handed a prescription for Pregabalin.

 

"The pain didn't go away," Phil says flatly. "But now I couldn't think straight either. I felt drunk. Confused. I stopped driving. Stopped seeing my grandchildren because I couldn't follow their stories."

 

Phil's story is not unique. It is epidemic.

 

According to NHS Inform, nearly 1 in 10 Britons over 55 suffer from peripheral neuropathy—a painful nerve disorder characterised by burning, stabbing, or 'electric shock' sensations.

 

Yet the standard treatment protocol remains shockingly inadequate: wait, take pills that dull your brain, or simply 'learn to live with it.'

 

What if there were another way?

 

A way that didn't involve waiting months for NHS appointments or numbing your mind with gabapentinoids?

 

What if the solution had been discovered in 1957 and then deliberately buried?

The Molecule Big Pharma Couldn't Patent

In the late 1950s, Czech scientist Dr. Jaroslav Kuehl isolated a curious fatty acid compound from egg yolks.

 

He called it Palmitoylethanolamide, or PEA for short.

 

Early studies showed remarkable anti-inflammatory properties, particularly in nerve-related pain.

 

But there was a problem: PEA occurs naturally in the human body. It's produced by your own cells in response to tissue damage. It's found in foods like peanuts, soya, and eggs.

 

Which meant pharmaceutical companies couldn't patent it.

 

And if they couldn't patent it, they couldn't profit from it.

 

By the 1970s, PEA research had slowed to a trickle. By the 1990s, it had stopped almost entirely in the UK.

 

Meanwhile, synthetic drugs like Gabapentin and Pregabalin—which could be patented—flooded the market.

 

Today, Pregabalin alone generates over £2 billion annually for its manufacturers.

 

"It's not a conspiracy," says Dr. Marcus Pemberton, a neuropharmacologist at Imperial College London.

 

"It's economics. Natural substances don't generate shareholder value. So they don't get marketed. They don't get prescribed. They disappear."

The 'Glial Cell Fire' Destroying Your Nerves

Here's what your GP didn't explain: nerve pain isn't caused by the nerve itself.

 

It's caused by immune cells called glial cells and mast cells that surround your nerves.

 

When these cells become chronically activated—due to diabetes, injury, chemotherapy, or simply aging—they release a cascade of inflammatory molecules.

 

One of the most damaging is called NF-kappa B.

 

Think of it as lighter fluid on a fire. It keeps the inflammation burning long after the original injury has healed.

 

Your nerve is trapped in a feedback loop of pain signals that never switches off.

 

Conventional painkillers—even strong ones—don't target this fire. They're like spraying air freshener in a burning house. The smoke might smell better, but the flames rage on.

The 'Biological Switch' That Changes Everything

This is where PEA becomes extraordinary.

 

Unlike drugs that merely block pain signals, PEA works at the genetic level to stop inflammation at its source.

 

PEA activates a receptor in your cells called PPAR-alpha.

 

When this receptor is triggered, it sends a signal directly to the nucleus of the glial cell—the control centre—instructing it to stop producing NF-kappa B and other inflammatory toxins.

 

In essence, PEA flips the biological switch from 'inflamed' to 'healing.'

 

The fire goes out.

The nerve begins to repair.

 

A 2024 systematic review published in the Journal of Pain Research analysed 24 double-blind, placebo-controlled trials involving over 2,400 patients with neuropathic pain.

 

The conclusion?

 

PEA significantly reduced pain intensity and improved quality of life, with zero serious side effects.

"We've seen PEA work where pregabalin failed. Patients report not just less pain, but better sleep, better mood, and—crucially—no cognitive impairment. It's remarkable how effective a natural lipid can be when delivered properly."

 

— Dr. Fiona Caldwell, Consultant Neurologist, Manchester Royal Infirmary

Why Ordinary PEA Creams Don't Work (And Why NerveSwitch™ Does)

Here's the catch: regular PEA molecules are too large to penetrate the skin.

 

Most PEA supplements are taken orally, which means they must survive stomach acid, pass through the liver, and circulate through your entire bloodstream before reaching the affected nerve—if they reach it at all.

 

Topical creams fare even worse.

 

Standard PEA particles are roughly 400-500 nanometres in diameter—far too large to slip through the skin's 20-nanometre pores.

 

Enter ultra-micronised PEA (um-PEA): particles ground down to less than 10 microns using a patented jet-milling process.

 

At this size, um-PEA can penetrate the stratum corneum—the skin's outermost layer—and deliver its payload directly to the inflamed nerve fibres beneath.

This is the technology behind NerveSwitch™ nerve lotion

Developed in collaboration with researchers at Cambridge University's Department of Clinical Neurosciences.

 

NerveSwitch™ combines pharmaceutical-grade um-PEA with alpha-lipoic acid (a powerful antioxidant proven to support nerve regeneration in diabetic neuropathy) in a fast-absorbing, non-greasy base.
 

Unlike menthol-based gels that merely distract from pain, or thick balms that leave your clothes stained and your skin clammy, NerveSwitch™ absorbs completely in under 20 seconds—what users have described as a 'silk texture.'

How NerveSwitch™ Compares

"I Got My Life Back" - Phil Kay discovered NerveSwitch™ through a support group for diabetic neuropathy patients.

 

Sceptical after years of disappointment, he ordered a single jar.

 

"I applied it before bed that first night," he recalls. "Within about 40 minutes, the burning started to ease. Not disappear—ease. Like someone had turned down the thermostat from 10 to about 6."

 

By the end of the first week, Phil was sleeping through the night for the first time in 18 months.

 

By week three, he was walking again—not six kilometres yet, but a slow, steady two kilometres around his neighbourhood.

 

"I'm not 'cured,'" Phil says carefully. "But I'm functional. I can hold my granddaughter without wincing. I can drive. I can think. That's everything."

 

Margaret Thornton, 68, from Edinburgh, battled breast cancer and won—only to be left with chemotherapy-induced peripheral neuropathy so severe she couldn't hold a pen.

 

"My oncologist said it might improve with time, but it didn't," she says.

 

"I tried acupuncture, TENS machines, gabapentin—nothing worked. NerveSwitch was different. It didn't just numb the pain; it felt like it was healing something. Within a month, I could knit again. That might sound small, but it meant the world."

"Too Good to Be True?"

It's a fair question...

 

The British public has been burned before by miracle creams and snake oil.

 

But NerveSwitch™ isn't marketed by some fly-by-night American company.

 

It's produced in a GMP-certified facility in Surrey, with batch testing conducted at an independent laboratory in Cambridge.

 

Every ingredient is listed transparently. Every claim is backed by peer-reviewed research published in journals like Pain Medicine and The Journal of Neuroinflammation.

 

More importantly, it works through a mechanism that's biologically plausible.

 

This isn't magic. It's pharmacology.

CHECK AVAILABILITY NOW

 

Why Now?

The NHS backlog for pain management clinics currently sits at over 18 months in some regions.

 

Pregabalin prescriptions continue to rise despite mounting evidence of dependency and cognitive harm.

 

Meanwhile, nerve damage is progressive—the longer inflammation persists, the harder it becomes to reverse.

 

You don't have to wait for permission from a GP who's drowning in paperwork.

 

You don't have to risk your mental clarity on gabapentinoids.

 

You don't have to accept that burning, stabbing, relentless pain as 'just part of getting older.'

 

You can take control of your own recovery. Today.

 

NerveSwitch™ Ultra is available exclusively through the manufacturer's website at www.getrevivecare.com. A 90-day satisfaction guarantee covers all first-time orders.

CHECK AVAILABILITY NOW

 

Next batch if sold out: February 21, 2026

ABOUT THIS REPORT

This investigative feature was researched independently by Dr. Eleanor Hartley, a medical journalist with 15 years' experience covering pain management and neurology.

 

While NerveSwitch™'s manufacturer provided scientific literature and access to clinical researchers, no payment was received for this article. All claims have been verified against peer-reviewed sources.

 

As with any health intervention, readers are advised to consult their GP before beginning a new treatment, particularly if taking prescription medications.

 

Selected References

1. NHS Inform. (2024). Peripheral neuropathy. Available at: www.nhsinform.scot

2. Briskey, D. et al. (2024). Palmitoylethanolamide in chronic pain treatment: A systematic review. Journal of Pain Research.

3. Paladini, A. et al. (2016). Palmitoylethanolamide: PPAR-alpha-mediated mechanism. Mediators of Inflammation.

4. Public Health England & NHS England. (2014).

1. Select product quantity in Official Store

2. Get yours delivered to your door and feel the difference.

APPLY DISCOUNT & CHECK AVAILABILITY 👉

CHECK AVAILABILITY NOW →